Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets
Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico
Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months
Lucia Ziegler, MSc
Head of Investor & Public Relations